Vestibo, pills 24mg 30pcs

Composition

1 tablet contains:

Active ingredient:

betahistine dihydrochloride 24 mg;

Auxiliary substances:

povidone K90;

MCC;

lactose monohydrate;

colloidal silicon dioxide;

crospovidone;

stearic acid;

purified water (not contained in the finished product).

Pharmacological action

Pharmacodynamics

Vestibo is a weak_H1-receptor agonist and a fairly potent_H3-receptor antagonist. It affects the cochlear blood flow and the central vestibular apparatus. The action of betahistine includes: vasodilation in the inner ear (mediated_{by H3-and H1}-receptors), an inhibitory effect on the vestibular nuclei (via_H3-receptors) and the pulse activity of ampullary receptors. By direct agonistic action on the_H1-receptors of the inner ear vessels and precapillary sphincters of the microcirculatory bed located in the vascular strip (stria vascularis), as well as indirectly through the_H3-receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea, increases blood flow in the basilar artery.

It has a pronounced central effect, being an antagonist_{of H3}-receptors of the vestibular nerve nuclei, normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. Indirectly acting on_H3-receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei.

Helps to eliminate disorders of both the vestibular and cochlear apparatus: reduces the frequency and intensity of dizziness, reduces tinnitus, improves hearing in cases of its decline. It stimulates_H1-receptors, so it does not have a sedative effect and does not cause drowsiness.

Pharmacokinetics

Absorbed quickly, binding to plasma proteins is low. C_max — 3 hours. It is almost completely excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. T_1/2 — 3-4 hours.

Indications

Dropsy of the inner ear labyrinth; vestibular and labyrinthine disorders: dizziness, noise and pain in the ears, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations), Meniere’s disease.

As part of complex therapy:

• vertebrobasilar insufficiency;
• post-traumatic encephalopathy;
• cerebral vascular atherosclerosis.

Use during pregnancy and lactation

Vestibo is contraindicated during pregnancy and in childhood.

Contraindications

• hypersensitivity;
• pheochromocytoma;
• pregnancy (I trimester).

With caution:

• peptic ulcer of the stomach or duodenum (in the anamnesis);
• pregnancy (II-III trimester);
• childhood.

Side effects

Dyspepsia (nausea, vomiting), skin rash, angioedema.

Interaction

When Vestibo is taken simultaneously with antihistamines, the effectiveness of treatment decreases.

How to take, course of use and dosage

Inside, while eating, without chewing, with a small amount of liquid.

1/2-1 tablet 2 times a day. The maximum daily dose is 48 mg.

Overdose

Symptoms:  headache, hyperemia of the facial skin, dizziness, tachycardia, decreased blood pressure Blood pressure, bronchospasm.

Special instructions

The therapeutic effect in some cases appears only a few months after the start of treatment.

Form of production

Pills.

Storage conditions

Store the drug in a dry place protected from light at a temperature not exceeding 22°C.

Shelf

life is 2 years.

Active ingredient

Betahistine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults, For adults as prescribed by a doctor

Indications

Meniere’s disease, Cerebrovascular Accident